Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 5;12(9):2715–2722. doi: 10.7150/jca.56397

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The author(s)

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

PMC Copyright notice

Survival outcomes and treatment failure rates among four patient subgroups according to the combinations of pre- and 3 months post-treatment plasma EBV DNA levels. (A) Progression-free survival. (B) Distant metastasis-free survival. (C) Locoregional relapse-free survival. (D) Overall survival. (E) Progression rate. (F) Distant metastasis rate. (G) Locoregional relapse rate. (H) Mortality rate. “Pre-” and “Pre+” denote negative and positive pre-treatment EBV DNA status, respectively; “Post-” and “Post+” denote negative and positive 3 months post-treatment EBV DNA status, respectively.